Mike Mensinger Sells 2,200 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,200 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the transaction, the insider owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Mike Mensinger also recently made the following trade(s):

• On Friday, January 2nd, Mike Mensinger sold 7,800 shares of Beta Bionics stock. The stock was sold at an average price of $29.61, for a total value of $230,958.00.
• On Tuesday, December 2nd, Mike Mensinger sold 1,063 shares of Beta Bionics stock. The shares were sold at an average price of $29.34, for a total value of $31,188.42.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $31.99 on Friday. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $32.71. The firm has a market cap of $1.41 billion and a PE ratio of -7.32. The company has a 50 day simple moving average of $29.43 and a 200 day simple moving average of $22.24.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. The firm had revenue of $27.25 million during the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors have recently bought and sold shares of BBNX. GPS Wealth Strategies Group LLC lifted its stake in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the last quarter. Strs Ohio bought a new stake in Beta Bionics in the 1st quarter worth about $29,000. Ameritas Investment Partners Inc. increased its stake in Beta Bionics by 139.1% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after buying an additional 1,863 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after buying an additional 2,639 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BBNX shares. Bank of America raised their price objective on Beta Bionics from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday. Piper Sandler reissued an “overweight” rating and set a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Lake Street Capital restated a “buy” rating and issued a $35.00 price target on shares of Beta Bionics in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Finally, The Goldman Sachs Group increased their price objective on shares of Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.